Breaking: Promising Sonelokimab's HS Trial Data Propels MoonLake Immunotherapeutics
- June 26th, 2023
- 214 views
MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company, announced positive results from its Phase 2 MIRA trial, evaluating the effectiveness and safety of the Nanobody sonelokimab, administered subcutaneously, in patients with moderate-to-severe hidradenitis suppurativa (HS).
Hidradenitis suppurativa is a painful skin condition characterized by lumps that form in areas where skin touches skin.
The trial successfully met its primary endpoint, with a higher proportion of patients treated with sonelokimab achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 compared to those on placebo at week 12.
The results showed that sonelokimab exhibits strong clinical activity compared to other therapies evaluated in similar trials.
At present, $MLTX is trading at $47.59, representing a significant increase of $21.71 (+83.89%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login